Citizens Maintains Market Outperform on Sutro Biopharma, Raises Price Target to $35

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and raises the price target from $23 to $35.